Journal Mobile Options
Table of Contents
Vol. 72, Suppl. 1, 2007
Issue release date: December 2007
Oncology 2007;72:117–123
(DOI:10.1159/000111717)

Evaluating Patients with Cirrhosis for Hepatocellular Carcinoma: Value of Clinical Symptomatology, Imaging and Alpha-Fetoprotein

Paul S.B. · Gulati M.S. · Sreenivas V. · Madan K. · Gupta A.K. · Mukhopadhyay S. · Acharya S.K.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Objective: This study was undertaken to assess the value of clinical symptomatology, abdominal ultrasound (US), triple-phase CT (TPCT) and serum alpha-fetoprotein (AFP) estimation in predicting presence of hepatocellular carcinoma (HCC) among patients with cirrhosis. Materials and Methods: In this cross-sectional study, Child’s A/B cirrhosis patients were subjected to clinical evaluation, US, TPCT and serum AFP estimation. Sensitivity and specificity of clinical symptoms and of AFP at different cut-off levels were determined. Detection rate of HCC and agreement between US and TPCT was estimated. Results: A high proportion of enrolled subjects had HCC at first presentation (40.7%). Significantly higher prevalence of abdominal pain, weight loss, and anorexia was seen in patients with cirrhosis with HCC compared to those without HCC. Sensitivity and specificity of any of these symptoms was 73 and 79%, respectively (positive and negative predictive values of 65 and 85%, respectively). A 100% agreement between TPCT and US was observed for diagnosing HCC cases. However, TPCT detected a greater number of smaller HCCs. Sensitivity of AFP at 400 ng/ml cut-off was only 25.7%, too low to be useful. Best mix of sensitivity (77.2%) and specificity (78.1%) of AFP was found to be at 10.7 ng/ml cut-off which falls within the conventional limits of normalcy. Conclusion: The study highlights the importance of symptomatology of weight loss, abdominal pain or anorexia as markers for HCC in patients with cirrhosis. AFP was not found to be a useful screening test. TPCT should be undertaken in all cirrhotics presenting to the hospital for the first time.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Llovet JM, Burroughs A, Bruix J: Hepatocelluar carcinoma. Lancet 2003;362:1907–1917.
  2. Fattovich G, Giustina G, Schalm SW, et al: Occurrence of hepatocellular carcinoma and decompensation in Western European patients with cirrhosis type B: the EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology 1995;21:77–82.
  3. Okuda K, Ohtuski T, Obata H, et al: Natural history of hepatocellular carcinoma and prognosis in relation to treatment: study of 850 patients. Cancer 1985;56:918–928.
  4. Sarin SK, Thakur V, Guptan RK, et al: Profile of hepatocellular carcinoma in India: an insight into the possible etiologic associations. J Gastroenterol Hepatol 2001;16:666–673.
  5. Batra Y, Gulati M, Paul SB, Acharya SK: Clinical profile and results of therapy in patients of HCC at a tertiary care center in India. J Gastroenterol Hepatol 2004;19:A799.

    External Resources

  6. Daniele B, Bencivenga A, Megna AS, Tinessa V: Alpha fetoprotein and ultrasonography screening for hepatocelluar carcinoma. Gastroenterology 2004;127:S108–S112.
  7. Sherman M: Alphafetoprotein: an obituary. J Hepatol 2001;34:603–605.
  8. Bruix J, Sherman M, Llovet JM, et al: EASL panel of experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona 2000 EASL Conference. European Association for the Study of Liver. J Hepatol 2001;35:421–430.
  9. Peterson MS, Baron RL: Radiologic diagnosis of hepatocellular carcinoma. Clin Liver Dis 2001;5:123–144.
  10. Talwalkar JA, Gores GJ: Diagnosis and staging of hepatocellular carcinoma. Gastroenterology 2004;127:S126–S132.
  11. Feefey SA, Hildeboldt CC, Dehdashti F, et al: Detection of primary hepatic malignancy in liver transplant candidates: prospective comparison of CT, MR imaging, US, and PET. Radiology 2003;226:533–542.
  12. Yao FY, Ferrell L, Bass NM, et al: Liver transplantation for hepatocellular carcinoma: expansion of the tumor size does not adversely impact survival. Hepatology 2001;33:1394–1403.
  13. Chalasani N, Horlander JC Sr, Said A, et al: Screening for hepatocellular carcinoma in patients with advanced cirrhosis. Am J Gastroenterol 1999;94:2988–2993.
  14. Tanaka S, Kitamura T, Imaoka S, et al: Hepatocellular carcinoma: sonographic and histological correlation. Am J Roentgenol 1983;140:701–707.
  15. Tanaka S, Kitamura T, Ahshima A, et al: Diagnostic accuracy of ultrasonography for hepatocellular carcinoma. Cancer 1986;58:344–347.
  16. Rao ARW, Chui AKK, Shi LW, et al: Sensitivity of radiological investigations in diagnosing hepatocellular carcinoma in cirrhotic liver. Transplant Proc 2003;35:348–349.
  17. Matsumoto Y, Suzuki T, Asadi T, et al: Clinical classification of hepatoma in Japan according to serial charges in serum alpha fetoprotein levels. Cancer 1982;49:354–336.
  18. Johnson J: Tumor marker in the diagnosis and management of patients with hepatocullular carcinoma. Recent Results Cancer Res 1986;100:68.
  19. Watanabe A, Yamamoto H, Ito T, et al: Diagnosis, treatment and prognosis of small hepatocellular carcinoma. Hepatogastroenterlogy 1986;33:52.
  20. Sherman M, Peltekian KM, Lee C: Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North-American urban population. Hepatology 1995;22:432–438.
  21. Trevisani F, D’Intino PE, Morselli-Labate AM, et al: Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 2001;34:570–575.
  22. Gambarin-Gelwan M, Wolf DC, Shapiro R, Schwartz ME, Min AD: Sensitivity of commonly available screening tests in detecting hepatocellular carcinoma in cirrhotic patients undergoing liver transplantation. Am J Gastroenterol 2000;95:1535–1538.
  23. Nguyen MH, Garcia RT, Simpson PW, Wright TL, Keeffe EB: Racial differences in effectiveness of alpha-fetoprotein for diagnosis of hepatocellular carcinoma in hepatitis C virus cirrhosis. Hepatology 2002;36:410–417.
  24. Peng YC, Chan CS, Chen GH: The effectiveness of serum alpha-fetoprotein level in anti-HCV positive patients for screening hepatocellular carcinoma. Hepatogastroenterology 1999;46:3208–3211.
  25. Cedrone A, Covino M, Caturelli E, et al: Utility of alpha-fetoprotein (AFP) in the screening of patients with virus-related chronic liver disease: does different viral etiology influence AFP levels in hepatocellular carcinoma? A study in 350 western patients. Hepatogastroenterology 2000;47:1654–1658.
  26. Tong MJ, Blatt LM, Kao VW: Surveillance for hepatocellular carcinoma in patients with chronic viral hepatitis in the United States of America. J Gastroenterol Hepatol 2001;16:553–559.
  27. Okuda K, Okuda H: Primary liver cell carcinoma; in Bircher J, Benhamou JP, McIntyre N, Rizzetto M, Rodes J (eds): Oxford Textbook of Clinical Hepatology, ed 2. Oxford, Oxford University Press, 1999, vol II, pp 1491–1530.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50